Table 1.
Patient characteristics.
| All Patients | Responders | Non-Responders | p Value | |
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Total number | 36 (100) | 18 (50) | 18 (50) | |
| Sex | 0.500 | |||
| Male | 21 (58.3) | 12 (67.7) | 9 (50.0) | |
| Female | 15 (41.7) | 6 (33.3) | 9 (50.0) | |
| Age | 0.740 | |||
| <60 | 18 (50.0) | 10 (55.6) | 8 (44.4) | |
| ≥60 | 18 (50.0) | 8 (44.4) | 10 (55.6) | |
| Median (range) | 59.5 (33–87) | 57 (40–84) | 61.5 (33–87) | |
| Histologic grade | 1.000 | |||
| low grade 1 | 33 (91.7) | 16 (88.9) | 17 (94.4) | |
| high grade 2 | 3 (8.3) | 2 (11.1) | 1 (5.6) | |
| Metastatic pattern | 1.000 | |||
| metachronous | 17 (47.2) | 8 (44.4) | 9 (50.0) | |
| synchronous | 19 (52.8) | 10 (55.6) | 9 (50.0) | |
| Primary tumor site | 0.500 | |||
| Colon | 21 (58.3) | 12 (66.7) | 9 (50.0) | |
| Rectum | 15 (41.7) | 6 (33.3) | 9 (50.0) | |
| Metastatic site | ||||
| Liver | 21 (58.3) | 8 (44.4) | 13 (72.2) | |
| Lung | 15 (41,7) | 9 (50.0) | 6 (33.3) | |
| Other | 15 (41.7) | 9 (50.0) | 6 (5.6) | |
| Number of metastatic sites | 1.000 | |||
| 1 | 21 (58.3) | 10 (55.6) | 11 (61.1) | |
| >1 | 15 (41.7) | 8 (44.4) | 7 (38.9) | |
| Treatment regimen | 0.603 | |||
| 1st line | 32 (88.9) | 15 (83.3) | 17 (94.4) | |
| 2nd line | 4 (11.1) | 3 (16.7) | 1 (5.6) | |
| PFS (months) | 0.001 | |||
| Median (range) | 9.8 (3.0–70.9) | 14.0 (7.5–70.9) | 9.2 (3.0–22.5) |
Statistical analysis was performed with the Fisher’s exact test or the Log-rank test, as appropriate. 1 Well-differentiated/moderately-differentiated. 2 Poorly-differentiated. PFS: progression-free survival.